Literature DB >> 12506018

Stimulation of osteoprotegerin production is responsible for osteosclerosis in mice overexpressing TPO.

Hédia Chagraoui1, Micheline Tulliez, Tarek Smayra, Emiko Komura, Stéphane Giraudier, Theodore Yun, Nathalie Lassau, William Vainchenker, Françoise Wendling.   

Abstract

Myelofibrosis and osteosclerosis are prominent features arising in mice overexpressing thrombopoietin (TPO). The pivotal role of transforming growth factor beta 1 (TGF-beta 1) in the pathogenesis of myelofibrosis has been documented, but the mechanisms mediating osteosclerosis remain unclear. Here, we used mice deficient in osteoprotegerin (OPG), a secreted inhibitor of bone resorption, to determine whether osteosclerosis occurs through a deregulation of osteoclastogenesis. Marrow cells from opg-deficient mice (opg(-/-)) or wild-type (WT) littermates were infected with a retrovirus encoding TPO and engrafted into an opg(-/-) or WT background for long-term reconstitution. The 4 combinations of graft/host (WT/WT, opg(-/-)/opg(-/-), opg(-/-)/WT, and WT/opg(-/-)) were studied. Elevation of TPO and TGF-beta 1 levels in plasma was similar in the 4 experimental groups and all the mice developed a similar myeloproliferative syndrome associated with severe myelofibrosis. Osteosclerosis developed in WT hosts engrafted with WT or opg(-/-) hematopoietic cells and was associated with increased OPG levels in plasma and decreased osteoclastogenesis. In contrast, opg(-/-) hosts exhibited an osteoporotic phenotype and a growth of bone trabeculae was rarely seen. These findings suggest that osteosclerosis in mice with TPO overexpression occurs predominantly via an up-regulation of OPG in host stromal cells leading to disruption of osteoclastogenesis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12506018     DOI: 10.1182/blood-2002-09-2839

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  20 in total

Review 1.  Bone disease in multiple myeloma.

Authors:  Øyvind Hjertner; Therese Standal; Magne Børset; Anders Sundan; Anders Waage
Journal:  Med Oncol       Date:  2006       Impact factor: 3.064

Review 2.  Preclinical models for drug selection in myeloproliferative neoplasms.

Authors:  Niccolò Bartalucci; Costanza Bogani; Alessandro M Vannucchi
Journal:  Curr Hematol Malig Rep       Date:  2013-12       Impact factor: 3.952

Review 3.  Bone marrow fibrosis in primary myelofibrosis: pathogenic mechanisms and the role of TGF-β.

Authors:  Archana Agarwal; Kerry Morrone; Matthias Bartenstein; Zhizhuang Joe Zhao; Amit Verma; Swati Goel
Journal:  Stem Cell Investig       Date:  2016-02-26

4.  Pathological interactions between hematopoietic stem cells and their niche revealed by mouse models of primary myelofibrosis.

Authors:  Lilian Varricchio; Annalisa Mancini; Anna Rita Migliaccio
Journal:  Expert Rev Hematol       Date:  2009-06-01       Impact factor: 2.929

5.  Osteomyelosclerosis, anemia and extramedullary hematopoiesis in mice lacking the transcription factor NFATc2.

Authors:  Wolfgang Bauer; Martina Rauner; Michael Haase; Satu Kujawski; Laleh S Arabanian; Ivonne Habermann; Lorenz C Hofbauer; Gerhard Ehninger; Alexander Kiani
Journal:  Haematologica       Date:  2011-07-12       Impact factor: 9.941

6.  Lnk Deficiency Leads to TPO-Mediated Osteoclastogenesis and Increased Bone Mass Phenotype.

Authors:  David J Olivos; Marta Alvarez; Ying-Hua Cheng; Richard Adam Hooker; Wendy A Ciovacco; Monique Bethel; Haley McGough; Christopher Yim; Brahmananda R Chitteti; Pierre P Eleniste; Mark C Horowitz; Edward F Srour; Angela Bruzzaniti; Robyn K Fuchs; Melissa A Kacena
Journal:  J Cell Biochem       Date:  2017-04-18       Impact factor: 4.429

7.  Circasemidian rather than circadian variation of circulating osteoprotegerin in clinical health.

Authors:  R Tarquini; G Mazzoccoli; S Dolenti; P Gaudiano; C Comuni; G Laffi; F Perfetto; K Otsuka; G Cornélissen; F Halberg
Journal:  Biomed Pharmacother       Date:  2005-10       Impact factor: 6.529

8.  Megakaryocyte and Osteoblast Interactions Modulate Bone Mass and Hematopoiesis.

Authors:  Marta B Alvarez; LinLin Xu; Paul J Childress; Kevin A Maupin; Safa F Mohamad; Brahmananda R Chitteti; Evan Himes; David J Olivos; Ying-Hua Cheng; Simon J Conway; Edward F Srour; Melissa A Kacena
Journal:  Stem Cells Dev       Date:  2018-05-15       Impact factor: 3.272

9.  Increased skeletal VEGF enhances beta-catenin activity and results in excessively ossified bones.

Authors:  Christa Maes; Steven Goossens; Sonia Bartunkova; Benjamin Drogat; Lieve Coenegrachts; Ingrid Stockmans; Karen Moermans; Omar Nyabi; Katharina Haigh; Michael Naessens; Lieven Haenebalcke; Jan P Tuckermann; Marc Tjwa; Peter Carmeliet; Vice Mandic; Jean-Pierre David; Axel Behrens; Andras Nagy; Geert Carmeliet; Jody J Haigh
Journal:  EMBO J       Date:  2009-12-10       Impact factor: 11.598

10.  The effect of anabolic steroids on anemia in myelofibrosis with myeloid metaplasia: retrospective analysis of 39 patients in Japan.

Authors:  Kazuya Shimoda; Kotaro Shide; Kenjirou Kamezaki; Takashi Okamura; Naoki Harada; Naoko Kinukawa; Kazuma Ohyashiki; Yoshiyuki Niho; Hideaki Mizoguchi; Mitsuhiro Omine; Keiya Ozawa; Mine Haradaa
Journal:  Int J Hematol       Date:  2007-05       Impact factor: 2.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.